Chemomab Announces Phase 2 Trial Results for Nebokitug in Primary Sclerosing Cholangitis Published in Gastroenterology Journal

Chemomab Therapeutics announced that its Phase 2 SPRING trial results for nebokitug in primary sclerosing cholangitis (PSC) were published in the American Journal of Gastroenterology. Nebokitug was found to be safe and well-tolerated in patients with PSC, with numerical improvements in biomarkers for inflammation and fibrosis. The study's authors conclude that the promising data support further evaluation of nebokitug in a Phase 3 clinical trial.